Evidence map›Paper›PMID 33547615›Full record

ReviewNeurochemical research2021

A Review on Potential Footprints of Ferulic Acid for Treatment of Neurological Disorders.

Surabhi Thapliyal, Tanveer Singh, Shailendra Handu, Manisha Bisht, Puja Kumari, Priyanka Arya, Pallavi Srivastava, Ravi Gandham

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neurochemical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
14.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 74 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Surabhi ThapliyalDepartment of Pharmacology, All India Institute of Medical Sciences, Rishikesh, 249203, India.
Tanveer SinghDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KT, 40508, USA.
Shailendra HanduDepartment of Pharmacology, All India Institute of Medical Sciences, Rishikesh, 249203, India. shailendra.handu@gmail.com.
Manisha BishtDepartment of Pharmacology, All India Institute of Medical Sciences, Rishikesh, 249203, India.
Puja KumariDepartment of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Priyanka AryaDepartment of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard (Hamdard University), 110062, New Delhi, India.
Pallavi SrivastavaDepartment of Pharmacology, All India Institute of Medical Sciences, Rishikesh, 249203, India.
Ravi GandhamDepartment of Pharmacology, All India Institute of Medical Sciences, Rishikesh, 249203, India.
All India Institute of Medical Sciences RishikeshJamia Hamdard · INPost Graduate Institute of Medical Education and Research · INUniversity of Kentucky · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferulic acid is being screened in preclinical settings to combat various neurological disorders. It is a naturally occurring dietary flavonoid commonly found in grains, fruits, and vegetables such as rice, wheat, oats, tomatoes, sweet corn etc., which exhibits protective effects against a number of neurological diseases such as epilepsy, depression, ischemia-reperfusion injury, Alzheimer's disease, and Parkinson's disease. Ferulic acid prevents and treats different neurological diseases pertaining to its potent anti-oxidative and anti-inflammatory effects, beside modulating unique neuro-signaling pathways. It stays in the bloodstream for longer periods than other dietary polyphenols and antioxidants and easily crosses blood brain barrier. The use of novel drug delivery systems such as solid-lipid nanoparticles (SLNs) or its salt forms (sodium ferulate, ethyl ferulate, and isopentyl ferulate) further enhance its bioavailability and cerebral penetration. Based on reported studies, ferulic acid appears to be a promising molecule for treatment of neurological disorders; however, more preclinical (in vitro and in vivo) mechanism-based studies should be planned and conceived followed by its testing in clinical settings.

Indexed as

AnimalsBrainCoumaric AcidsHumansNerve Tissue ProteinsNervous System DiseasesNeuroprotective AgentsSignal TransductionCoumaric Acidsferulic acidNerve Tissue ProteinsNeuroprotective AgentsAlzheimer’s diseaseDepressionEpilepsyFerulic acidIschemia‐reperfusion injuryParkinson’s disease

Identifiers

PMID33547615
OpenAlexW3129191787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.